Microbes linked to pancreatic cancer and early pancreatic lesions
Official title: The Role of Microbiota in Pancreatic Cancer and Precursor Lesions
Run by Herlev Hospital · NCT07250100 · Data updated 2026-11-12
This will see if microbes from the mouth, stool, and pancreas can help diagnose or predict outcomes for adults with suspected pancreatic lesions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Herlev Hospital Academic / other |
| Locations | 1 site (Herlev, Capital Region) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | October 2030 |
| Study ends | December 2037 |
| Registry record updated | November 26, 2025 |
| Trial ID | NCT07250100 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a suspected pancreatic lesion who are scheduled for a diagnostic or therapeutic endoscopic procedure and can give informed consent are eligible.
✕Probably not a fit
People without suspected pancreatic lesions or those who cannot undergo endoscopic or surgical procedures (for example due to uncorrected coagulopathy) are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational study enrolling adults with suspected solid or cystic pancreatic lesions who are undergoing diagnostic or therapeutic endoscopic procedures. Participants complete a questionnaire and provide oral and fecal swabs, and if clinically indicated clinicians will collect one or two pancreatic biopsies during standard care procedures. Collected samples will be analyzed for microbial composition and potential biomarkers and correlated with clinical findings and outcomes. The aims are to identify microbial signatures that improve diagnostic accuracy, inform prognosis, and help shape screening strategies for high-risk individuals.
Why it matters
Potential benefit: If successful, the work could enable earlier or more accurate diagnosis and better prediction of treatment response for patients with pancreatic lesions.
How similar studies have gone: Previous research has found associations between microbiome patterns and pancreatic cancer, but microbial biomarkers are not yet established for routine clinical diagnosis or prognosis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a suspected lesion (solid/cystic) in the pancreas undergoing diagnostic or therapeutic endoscopic procedure * Age of 18 years or above * Signed informed consent form Exclusion Criteria: * Contraindications for endoscopic or surgical procedure, such as uncorrected coagulopathy
Where it's running
-
Herlev og Gentofte Hospital
Herlev, Capital Region, Denmark Recruiting
Study contacts
- Study coordinator: Bojan Kovacevic, ph.d., MD
- Email: bojan.kovacevic@regionh.dk
- Phone: 0045 3868 6312
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)
This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.